Yes, targeting CAMs holds therapeutic potential in cancer treatment. Inhibitors of integrins, for example, have been explored to block cancer cell adhesion, migration, and invasion. Monoclonal antibodies and small molecule inhibitors targeting specific CAMs are under investigation to disrupt tumor progression and metastasis. Additionally, targeting CAM-mediated signaling pathways can provide a strategy to overcome drug resistance.
